China Tightens Grip on Veterinary Pharmaceuticals

15/09/2025

China is moving decisively to reshape its veterinary pharmaceutical industry. From early 2026, new regulations will enforce stricter Good Manufacturing Practice (GMP) certification, expand routine inspections, and raise penalties for non-compliance. Online veterinary drug sales — a booming segment during the pandemic — will also face tighter control.

The scale of the sector makes this significant. China already represents over 30% of global feed additive and veterinary drug demand, with its domestic market valued at more than USD 12 billion annually. The regulatory drive reflects Beijing’s intent to consolidate control over a sector closely tied to national food security and rural stability.

For multinational players like Zoetis, Elanco, and Merck Animal Health, the shift is a double-edged sword. Compliance costs and administrative hurdles are expected to rise, potentially limiting short-term margins. However, stricter rules may also push weaker local producers out of the market, opening opportunities for partnerships and joint ventures with firms able to meet higher standards.

Exporters into China face a different challenge: longer import testing, higher compliance requirements, and potential delays in product approvals. This could reconfigure global supply chains, particularly for high-value vaccines and biologics.

China’s approach underscores a broader trend: animal health regulation is increasingly treated as a matter of national strategy rather than just industry oversight. As Beijing tightens control, global veterinary pharma will need to adapt to a more complex, state-driven environment.